|55 Kenosia Avenue
Danbury, CT 06810
Toll Free: 1.800.999.6673
The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and the credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions is strictly prohibited.
The information in NORD’s Rare Disease Database is for educational purposes only. It should never be used for diagnostic or treatment purposes. If you have questions regarding a medical condition, always seek the advice of your physician or other qualified health professional. NORD’s reports provide a brief overview of rare diseases. For more specific information, we encourage you to contact your personal physician or the agencies listed as “Resources” on this report.
NORD is very grateful to Helge Hartung, MD, Attending Physician, Children's Hospital of Philadelphia, Division of Hematology, for assistance in the preparation of this report.
Factor VII deficiency is a rare genetic bleeding disorder characterized by a deficiency or reduced activity of clotting factor VII. Clotting factors are specialized proteins that are essential for the blood to clot normally. Individuals with factor VII deficiency can experience prolonged, uncontrolled bleeding episodes. The severity of factor VII deficiency can vary greatly from one person to another. Some individuals may have no symptoms (asymptomatic); others may develop mild, moderate or potentially severe, life-threatening complications as early as in infancy. Factor VII deficiency is caused by mutations of the F7 gene and is inherited as an autosomal recessive disorder.
Factor VII deficiency was first described in the medical literature by Dr. Alexander, et al. in 1951 and was referred to as prothrombin conversion accelerator deficiency. The disorder has also been known as Alexander's disease. In extremely rare instances, factor VII deficiency can be acquired during life; this report deals with the genetic form, which is present at birth (although symptoms may develop later).
The symptoms and severity of factor VII deficiency are highly variable; no consistent correlation between the amount of factor VII in the blood and overall severity is seen. Some individuals may not develop any symptoms (asymptomatic), including individuals with relatively low levels of factor VII. Other individuals may have mild cases that are only apparent after trauma or surgery. Mild symptoms can include chronic nosebleeds, easy bruising, and bleeding from the gums. Affected women may develop heavy and prolonged periods (menorrhagia).
More serious bleeding complications occur in some individuals and may mimic bleeding patterns seen in hemophilia. Bleeding into the joints (hemarthrosis) can result in progressive joint damage and degeneration, eventually limiting the range of motion of an affected joint. Soft tissue bleeding can result in bruising that seems spontaneous or out of proportion to an injury. Affected individuals can develop masses of congealed blood called hematomas that can cause symptoms due to compression of nearby structures or organs. Bleeding in the stomach, intestines and urogenital tract can also occur resulting in blood in the urine (hematuria) or black, tarry, bloody stools (melena or hematochezia).
Bleeding in severe factor VII deficiency can result in life-threatening complications. These include major gastrointestinal bleeds as well as head bleeds (intracranial hemorrhage), often during the first few weeks or months of life. Although quite rare, head bleeds have been reported in adults as well.
Individuals with factor VII deficiency may experience bleeding after surgery or minor procedures or following trauma or injury. Affected women may bleed excessively following childbirth (postpartum bleeding). Some newborns have experienced abnormal bleeding from the umbilical cord stump at birth.
Factor VII deficiency is caused by mutations of the F7 gene. These mutations are inherited in an autosomal recessive manner. Genetic diseases are determined by the combination of genes for a particular trait that are received from the father and the mother.
Recessive genetic disorders occur when an individual inherits the same abnormal gene from each parent. If an individual receives one normal gene and one gene for the disease, the person will be a carrier for the disease, but usually will not show symptoms. The risk for two carrier parents to both pass on the defective gene and, therefore, have an affected child is 25 percent with each pregnancy. The risk to have a child who is a carrier like the parents is 50 percent with each pregnancy. The chance for a child to receive normal genes from both parents and be genetically normal for that particular trait is 25 percent. The risk is the same for males and females.
The F7 gene creates (encodes) factor VII, which is a clotting factor. Clotting factors are specialized proteins that play an essential role in enabling the blood to clot. Clotting is the process by which blood clumps together to plug the site of a wound to stop bleeding. Clotting requires a series of reactions to ultimately form a clot to plug a wound. This is referred to as the clotting (coagulation) cascade. The clotting cascade involves different substances in addition to clotting factors. Factor VII, which is produced (synthesized) in the liver, eventually interacts with other clotting factors and certain cells or substances, e.g. platelets or fibrinogen, to help to form a clot. Mutations of the F7 gene result in deficient levels of functional factor VII, which in affected individuals, prevents the blood from clotting properly. Consequently, affected individuals have difficulty stopping the flow of blood from a wound; but they do not bleed faster or more profusely than healthy individuals.
Individuals with factor VII deficiency often have varying levels of residual factor VII deficiency. In many disorders, the amount of residual protein activity correlates with the severity of the disease (e.g. little to no residual protein activity results in severe disease). However, in factor VII deficiency the severity of the disorder does not always correlate with the residual activity of factor VII, suggesting that additional genetic and environmental factors play a role in the severity of the disorder.
Factor VII deficiency affects males and females in equal numbers. The disorder is estimated to affect 1 in 300,000 to 500,000 individuals in the general population. However, many cases of factor VII deficiency go undiagnosed or misdiagnosed, making it difficult to determine the true frequency in the general population. The incidence of factor VII deficiency tends to be higher in countries where marriage to close relatives (consanguineous marriage) is more common. According to the medical literature, more than 200 cases of true factor VII deficiency have been reported. Because of the variable severity of factor VII deficiency, the age of presentation can vary widely from birth until adulthood.
Symptoms of the following disorders can be similar to those of factor VII deficiency. Comparisons may be useful for a differential diagnosis.
Acquired factor VII deficiency is a general term for individuals who develop factor VII deficiency that is not inherited, but acquired at some point during life. Acquired factor VII deficiency can result from severe liver disease, sepsis or vitamin K deficiency. Certain drugs such as warfarin (Coumadin®) can result in acquired factor VII deficiency. Acquired factor VII deficiency is more common than the inherited form.
Combined deficiency of vitamin K-dependent clotting factors (VKCFD) is a rare inherited disorder in which individuals have abnormalities affecting several clotting factors, specifically factors II, VII, IX, and X. These four factors are known as the vitamin K-dependent factors because vitamin K is required for the chemical reactions to produce (synthesize) these factors. Individuals with VKCFD cannot form blood clots properly. The severity of the disorder can vary greatly from one person to another. Many individuals may only develop mild symptoms, although cases associated with severe complications can develop. Symptoms can include easy bruising, frequent nosebleeds, gastrointestinal bleeding, and bleeding into the soft tissue and muscle. Bleeding in the joints can also occur. VKCFD is inherited as an autosomal recessive disorder.
A diagnosis of factor VII deficiency is based upon identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation and a variety of specialized blood tests.
Clinical Testing and Work-Up
Specialized tests will include screening coagulation tests that measure how long it takes the blood to clot, specifically two tests known as activated partial thromboplastin time (aPTT) and prothrombin time (PT). Individuals with factor VII deficiency have a normal aPTT and a prolonged PT.
Further tests known as assays are required to confirm a diagnosis. An assay is a test that can measure the activity of certain substances in the blood. In affected individuals a factor VII assay will demonstrate reduced activity of factor VII.
The specific therapeutic procedures and interventions for individuals with factor VII deficiency depend primarily on the severity of the individual's disease. Factors that will influence therapy decisions include specific symptoms present; the natural course of the disorder including underlying cause (congenital versus acquired); an individual's age and overall health (e.g., concomitant disease), risks of certain medications or procedures, personal preference; and other factors. Decisions concerning the use of particular therapeutic interventions should be made by physicians and other members of the healthcare team, in careful consultation with the patient and/or parents, and based upon the specifics of the individual's case. Such a discussion will review the potential benefits and risks including possible side effects and long-term effects; consider patient preferences; and include other appropriate factors in order to come to a consensus.
Specific treatment options for acute bleeds in individuals with factor VII deficiency include recombinant factor VII, prothrombin complex concentrates, and fresh frozen plasma. Antifibrinolytics such as aminocaproic acid can help alleviate the bleeding symptoms.
NovoSeven® RT is a genetically engineered (recombinant) version of factor VII. Because it does not contain human blood or plasma, there is no risk of transmitting blood-borne viruses or other pathogens. NovoSeven has been well-tolerated and associated with few side effects. NovoSeven has been approved by the Food and Drug Administration (FDA) to treat bleeding episodes of individuals with congenital factor VII deficiency. NovoSeven® RT is manufactured by the pharmaceutical company Novo Nordisk. For more information, contact:
Novo Nordisk Inc.
100 College Road West
Princeton, NJ 08540
NovoSeven® RT Coagulation Factor VIIa (Recombinant)
Individuals with factor VII deficiency have also been treated with prothrombin complex concentrates (PCCs), which are blood products that contain a concentrated form of four different clotting factors: II, VII, IX and X. However, the amount of each specific factor contained in these products can vary from one preparation to another, making it difficult to determine the most appropriate dosage. PCCs undergo a purification process to eliminate viruses and other pathogens. PCCs are associated with an increased risk of developing blood clots, especially following repeated administration.
Theoretically, factor VII deficiency can be treated with fresh frozen plasma. However, in clinical practice the very large volume required to stop bleeding renders this impractical, primarily due to the short half-life of factor VII. Half-life refers to the time it takes for half of the infused factor to breakdown and to disappear from the bloodstream.
Some individuals with factor VII deficiency may undergo preventative (prophylactic) therapy in an attempt to prevent or minimize future bleeding complications. Prophylactic therapy has been used for individuals with a history of bleeding into the joints or the brain. The decision to undergo prophylactic therapy in factor VII deficiency is made after careful consultation with a patient's medical team. The specific prophylactic regimen in factor VII deficiency is case dependent.
Additional treatment options for individuals with factor VII deficiency are symptomatic and supportive. For example, excessive menstrual bleeding in women may be treated by birth control pills or drugs known as antifibrinolytics. Genetic counseling may be of benefit for affected individuals and their families.
Individuals with factor VII deficiency will benefit from a referral to a federally-funded hemophilia treatment center. These specialized centers can provide comprehensive care for individuals with hemophilia and rare bleeding disorders, such as factor VII deficiency. The treatment center's medical team, headed by a hematologist with expert knowledge in bleeding disorders, will develop specific treatment plans and organize the monitoring and long term follow up of affected individuals, thus ensuring state-of-the-art medical care. Treatment at a hemophilia treatment center ensures that individuals and their family members will be cared for by a professional healthcare team (physicians, nurses, physical therapist, social worker and genetic counselor) experienced in treating individuals with rare bleeding disorders.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. Government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
For information about clinical trials sponsored by private sources, contact:
400-1255 University Street
Quebec, H3B 3B6 Canada
Phone #: 514-848-0503
800 #: 800-668-2686
Home page: http://www.hemophilia.ca
333 East 38th Street, Suite 830
New York, NY 10016-2745
Phone #: 212-297-4336
800 #: --
Home page: http://www.childrenscbf.org/
PO Box 8126
Gaithersburg, MD 20898-8126
Phone #: 301-251-4925
800 #: 888-205-2311
Home page: http://rarediseases.info.nih.gov/GARD/
210 7th St. SE
Washington, DC 20003 USA
Phone #: 202-675-6984
800 #: 800-230-9797
Home page: http://www.hemophiliafed.org
Dublin, 7 Ireland
Phone #: 353-016-579900
800 #: N/A
Home page: http://www.haemophilia.ie/
116 West 32nd Street, 11th Floor
New York, NY 10001 USA
Phone #: 212-328-3700
800 #: 800-424-2634
Home page: http://www.hemophilia.org
P.O. Box 30105
Bethesda, MD 20892-0105
Phone #: 301-592-8573
800 #: --
Home page: http://www.nhlbi.nih.gov/
1425 René Lévesque Blvd. W. Suite 1010
Quebec, H3G 1T7 Canada
Phone #: 514-875-7944
800 #: --
Home page: http://www.wfh.org/index.asp?lang=EN
Todd T, Perry DJ. A review of long-term prophylaxis in the rare inherited coagulation factor deficiencies. Haemophilia. 2010;16:569-583. http://www.ncbi.nlm.nih.gov/pubmed/19906159
Mandhyan R, Tiwari A, Cherian G. Congenital factor VII deficiency. Br J Anaesth. 2010;2:267-268.
Boltin D, Boguslavski V, Goor Y, Elkayam. Primary factor VII deficiency. IMAJ. 2008;10:275-276. http://www.ima.org.il/imaj/ar08june-22.pdf
Mariani G, Lapecorella M, Dolce A. Steps toward an effective treatment strategy in congenital factor VII deficiency. Semin Hematol. 2006;43:S42-S47. http://www.ncbi.nlm.nih.gov/pubmed/16427385
Mariani G, Konkle BA, Ingersley J. Congenital factor VII deficiency: therapy with recombinant activated factor VII - a critical appraisal. Haemophilia. 2006;12:19-27. http://www.ncbi.nlm.nih.gov/pubmed/16409171
Acharya SS, Coughlin A, Dimichele M. Rare bleeding disorders registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost. 2004;2:248-256. http://www.ncbi.nlm.nih.gov/pubmed/14995986
Friederich PW, Henny CP, Messelink EJ, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomized trial. Lancet. 2003;361:201-205. http://www.ncbi.nlm.nih.gov/pubmed/12547542
Hartung H. Pediatric Factor VII Deficiency. Emedicine Journal, March 25, 2011. Available at: http://emedicine.medscape.com/article/960592-overview Accessed: February 5, 2012.
Ramanarayanan J, Krishnan GS. Factor VII. Emedicine Journal, May 19, 2011. Available at: http://emedicine.medscape.com/article/209585-overview Accessed: February 5, 2012.
Giansily-Blaizot M. Inherited Factor VII Deficiency. Orphanet encyclopedia, June 2004. Available at: http://www.orpha.net/data/patho/Pro/en/FactorVIIDeficiency-FRenPro916.pdf Accessed: February 5, 2012.
Report last updated: 2012/05/23 00:00:00 GMT+0